A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects with Recurrent, Non-enhancing, IDH1 Mutant, Low-grade Glioma. (AG120-881-C-001)
Clinical Trial Grant
Awarded By
Agios Pharmaceuticals, Inc.
Start Date
March 20, 2018
End Date
March 31, 2025
Awarded By
Agios Pharmaceuticals, Inc.
Start Date
March 20, 2018
End Date
March 31, 2025